The Future of Pharma Manufacturing: Trends That Will Shape CDMO Partnerships in 2025
American Injectables
American Injectables is a US based sterile injectable manufacturer focused on inpatient markets
If there’s one thing you can count on in the pharmaceutical industry — it’s that things will always change. From the rise of direct-to-consumer programs to the growing prevalence of chronic diseases, new trends demand new solutions. In this edition, we’ll explore the causes and effects of the shifts set to define 2025.?
Rise in direct-to-consumer programs?
In the past, patients have been highly dependent on their healthcare provider to manage chronic diseases like diabetes, obesity, migraines, and anxiety. Now patients have more choices about how and where they receive care. Telehealth enables them to get a prescription from a doctor and order a drug within minutes online.?
The rise in direct-to-consumer (DTC) programs is likely to significantly impact CDMO manufacturing partnerships in several ways. Firstly, there will be an increased demand for flexibility and speed in production to meet the needs of consumers who expect quick access to medications. CDMOs will need to adapt to shorter production cycles and more personalized manufacturing processes to cater to specific consumer demands.
Secondly, the focus on DTC programs will require CDMOs to enhance their technological capabilities, integrating digital solutions that facilitate collaboration with pharmaceutical companies. This integration will be crucial for managing the logistics of direct sales and ensuring that products reach consumers efficiently.
Lastly, as pharmaceutical companies engage more directly with consumers, there will be a greater emphasis on quality and compliance. CDMOs will need to maintain high standards to ensure that products meet regulatory requirements and consumer expectations. This shift may also lead to stronger partnerships, as pharmaceutical companies seek reliable CDMOs that can consistently deliver high-quality products in a consumer-driven market.
?? Key consideration: Is your drug eligible for a direct-to-consumer program??
Increase in chronic diseases?
The number of people with a chronic disease — such as cancer, diabetes, cardiovascular conditions, and autoimmune disorders — is on the rise. According to a study published in the National Library of Medicine, the number of people 50 years and older with at least one chronic disease is estimated to increase by 99.5% from 71.522 million in 2020 to 142.66 million by 2050.
To combat this, many drug makers are turning to injectable solutions. They offer targeted delivery, potency, and rapid action, making them invaluable in managing these complex, long-term conditions. For cancer patients, injectable therapies can deliver powerful drugs directly to tumor sites, while diabetics benefit from the precise control offered by injectable insulins. As these and other chronic diseases continue to affect larger portions of the population, the demand for injectable medicines is expected to rise alongside it.
领英推荐
?? Key consideration: How can you fill the need for chronic disease treatments??
Want more trends? Check out our blog on the rising demand for injectable medicines and low-cost generics.?
Shift toward western manufacturing?
The pharmaceutical industry is increasingly turning to U.S.-based CDMOs? for strategic and regulatory reasons:?
The proximity to these domestic organizations facilitates faster communication and development cycles, leading to shorter lead times and better collaboration. This can be a significant advantage in a competitive market. However, the shift also comes with higher operational costs, which may necessitate budget adjustments.?
?? Key consideration: Could your project benefit from onshoring production??
Next up: Going beyond the RFP
For more pharma insights and trends, subscribe to our newsletter. Our next edition lands in December: "Beyond the RFP: Unconventional Ways To Evaluate CDMO Partners.” Don’t miss out; Subscribe now.?
About American Injectables?
American Injectables is a growing CDMO based in the USA. Specializing in vials and syringes, they offer end-to-end solutions — from formulation to patient-ready products. If you’re looking for a flexible partnership with an experienced team, learn more at americaninj.com.?